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a  b  s  t  r  a  c  t
The  classical  view  that  only  adaptive  immunity  can  build  immunological  memory  has  recently  been
challenged.  Both  in organisms  lacking  adaptive  immunity  as  well  as  in  mammals,  the  innate  immune
system  can  adapt  to  mount  an  increased  resistance  to reinfection,  a de  facto innate  immune  memory
termed  trained  immunity.  Recent  studies  have  revealed  that  rewiring  of  cellular  metabolism  induced
by  different  immunological  signals  is a  crucial  step  for determining  the epigenetic  changes  underlying
trained  immunity.  Processes  such  as  a shift  of glucose  metabolism  from  oxidative  phosphorylation  toeywords:
onocyte
acrophage
lycolysis
pigenetics
rained immunity
aerobic  glycolysis,  increased  glutamine  metabolism  and  cholesterol  synthesis,  play  a crucial  role  in  these
processes.  The  discovery  of  trained  immunity  opens  the  door  for the  design  of  novel generations  of
vaccines,  for  new  therapeutic  strategies  for the treatment  of  immune  deﬁciency  states,  and  for  modulation
of exaggerated  inﬂammation  in  autoinﬂammatory  diseases.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).mmunometabolism
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Classically, the immune system can be divided into innate and
adaptive immunity, with monocytes, macrophages, neutrophils,
and NK cells as the main cellular effectors of innate immune
responses, while T- and B-lymphocytes mediate adaptive immu-
nity. Until recently it was  assumed only the adaptive immune
system possesses the capacity to mount a memory response and
therefore improve the immunological reaction to a second infec-
tion. However, an increasing amount of evidence accumulates,
suggesting that also the innate immune system possesses adap-
tive characteristics. In plants and non-vertebrates, both lacking an
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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daptive immune system, it has already been know for several
ecades that a memory response could be build that would pro-
ect from a secondary infection [1,2]. Interestingly, this improved
econdary response is not always strictly speciﬁc, as infection with
ne pathogen can sometimes also protect from infections with
on-related pathogens [3]. This process has been shown to be epi-
enetically regulated [4]. In retrospect, this (non-speciﬁc) memory,
ediated by the innate immune system, was also seen in mice
trains with known deﬁciencies in adaptive immune responses
3,5].
More recently, this same process of innate immune mem-
ry was also been shown to occur in human monocytes and
acrophages. -glucan, a major component of the C. albicans
ell wall, was shown to ex vivo enhance cytokine production to
 second unrelated stimulus, a process that was also epigenet-
cally regulated [6,7]. Also in mice, an in vivo challenge with
-glucan protected from subsequent C. albicans or S. aureus infec-
ion [6,8], and infection with cytomegalovirus induced improved
ffector function of NK cells after the infection [9]. In humans,
accination with Bacillus Calmette-Guérin (BCG) showed non-
peciﬁc protection from all-cause mortality, mainly a result of
educed mortality from infections, in low-weight birth children
n West-Africa [10,11]. In a vaccination study in healthy adult
olunteers, BCG markedly increased ex vivo cytokine responses
y inducing epigenetic reprogramming in myeloid cells [12].
hese studies demonstrate that the innate immune system can
dapt after a previous challenge through functional and epige-
etic reprogramming, a process that has been termed trained
mmunity or innate immune memory [13,14]. On the one hand,
rained immunity is likely an important host defense mecha-
ism contributing to the maturation of the innate immune system
f infants and mediating protection after certain infections or
accinations. On the other hand, when induced inappropriately
y endogenous stimuli, trained immunity may  play a role in
he pathogenesis of autoinﬂammatory and/or autoimmune dis-
ases [14,15]. Therefore, better understanding of the molecular
echanisms of trained immunity is crucial for developing new
ays of immunotherapy and targeting inﬂammatory disorders
14].
In the last years an increasing amount of evidence has been
ccumulated in support of the concept that cellular metabolism
s correlated with the functional state of immune cells [16]. Some
f the ﬁrst observations reported that different subsets of lympho-
ytes had distinctly different cellular metabolic states. Activated T
ymphocytes have high rates of both glycolysis and oxidative phos-
horylation (OxPhos) and metabolize glucose to lactate [17,18],
hereas memory T-lymphocytes are more dependent on lipid syn-
hesis via mitochondrial citrate production. These lipids can be
sed to produce triacyglycerides (TAGs) which are being degraded
y -oxidation to fuel OxPhos via acetyl-CoA production [19]. In
ontrast, regulatory T-cells fuel -oxidation and OxPhos through
xogenously derived fatty acids [20]. This shows that the pheno-
ype of lymphocytes highly correlates with the source of energy
hat they use [21,22]. Subsequent studies showed that different
henotypes of macrophages retrieve energy from very distinct
etabolic pathways: the more inﬂammatory (M(IFN) or formerly
1)  macrophages depend largely on glycolysis and show impaired
xPhos and disruption of the Tricarboxylic acid (TCA) cycle [23,24],
hile in the more anti-inﬂammatory (M(IL-4) or formerly M2)
acrophages the Krebs cycle is intact as they rely on OxPhos [25,26]
nd furthermore show increased -oxidation as a result of fatty acid
ptake [27].In this review we will focus on the metabolic pathways induced
y innate immune training. We  will discuss glycolysis, TCA cycle,
lutamine, and cholesterol metabolism and discuss their (poten-unology 28 (2016) 425–430
tial) effect on epigenetics and how these clues could be used as
therapeutic targets.
2. Metabolic pathways in trained immunity
2.1. Glycolysis
A metabolic switch from oxidative phosphorylation to gly-
colysis resulting in more lactate production has been described
in the highly metabolically active cancer cells already in the
beginning of the last century by Otto Warburg, called thus the
‘Warburg effect’ [28]. Glycolysis is often increased during immune
cell activation: activated T cells show increased rates of glycol-
ysis [17,18] and proinﬂammatory macrophages increase glucose
metabolism resulting in increased lactate production [24]. This
switch is assumed to be important as glycolysis, although being less
efﬁcient in generating adenosine triphosphate (ATP), can be upreg-
ulated multiple folds and therefore results in a faster production of
ATP compared to oxidative phosphorylation [28].
A similar switch is seen in -glucan trained monocytes [29]
(Fig. 1). Transcriptional and epigenetic (H3K4me3 and H3K27ac)
analysis of -glucan induced trained immunity in monocytes
revealed that genes in the mTOR signalling pathway and several
metabolic pathways, especially glycolysis, were highly induced
[7,29]. When human monocytes are stimulated in vitro with -
glucan for 24 h and let to rest for 6 subsequent days, the amounts of
glucose consumption and lactate production increased over time. In
contrast, oxygen consumption 6 days after -glucan training is sig-
niﬁcantly decreased compared to control macrophages [29]. These
effects of -glucan-induced training were mediated by activation
of the Akt/mTOR/Hif1 pathway. Inhibiting this pathway at sev-
eral levels, or making use of myeloid cell speciﬁc Hif1 knockout
mice, abrogated induction of trained immunity both at cytokine
and epigenetic level [29] (Fig. 1).
Induction of glycolysis results in higher ratios of NAD+/NADH
ratio, which was  also the case in -glucan trained mono-
cytes/macrophages [29]. In LPS stimulated monocytes the vast
increase in NAD+/NADH ratio has been shown to activate sirtuin 1
and 6, supporting a switch from a proinﬂammatory state with high
rates of glycolysis to a more anti-inﬂammatory state with increased
fatty acid oxidation [30]. Interestingly, in -glucan trained mono-
cytes, sirtuin 1 expression appeared to be decreased and activation
of sirtuin 1 by resveratrol inhibited training [29]. This suggests that
decreased expression of sirtuin 1 might play a role in the signiﬁcant
increase of H3K27ac induced by monocyte training by -glucan.
However, apart from the classical role as histone deacetylases, sir-
tuins were also shown to deacetylate nonhistone structutes, such
as NF-B or Hif1 [31], and this should be taken into consideration
too. Moreover, lactate, the end product of anaerobic glycolysis, is
also able to inhibit histone deacetylase (HDAC) activity and there-
fore cause increased gene accessibility [32].
In addition to its direct role in energy production, induction of
glycolysis might also play a role in posttranslational modiﬁcation
of effector molecules. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), one of the enzymes in glycolysis can bind the 3′ UTR  of
ifng RNA and therefore decreasing IFN production. In activated
T cells GAPDH is used in glycolysis and therefore more IFN can
be produced. Also decreasing GAPDH expression by RNA inter-
ference increased IFN production [33]. A similar mechanism has
been reported in murine and human monocytes and macrophages
in relation to TNF mRNA induction. GADPH can posttranscription-
ally repress TNF mRNA in monocytes in low glycolysis state, e.g.
immunotolerant monocytes as seen in sepsis [34] (Fig. 2). Whether
reversal of such effects plays a role in trained immunity remains to
be elucidated.
R.J.W. Arts et al. / Seminars in Immunology 28 (2016) 425–430 427
Fig. 1. Glucose metabolism in trained immunity. Induction of trained immunity by -glucan causes activation of the mTOR pathway, effect mediated through signalling via
the  dectin-1 receptor, which results in an increase of Hif1 activity, a central regulating transcription factor of glycolysis-related genes. This results in an upregulation of
glycolysis. Pyruvate, the end product of glycolysis, can be used to fuel the TCA cycle to produce NADH or FADH2, metabolic components that could be used in the electron
transport chain for oxidative phosphorylation (OxPhos). In -glucan trained monocytes pyruvate is converted into lactate, which although less efﬁcient than OxPhos, results
in  more ATP production, as it can be upregulated to a great extent.
Fig. 2. Overview of the complex metabolic pathways that could play a role in trained immunity. Induction of glycolysis resulting in lactate production is one of the central
hallmarks in trained immunity metabolism. In addition, glutamine metabolism, which fuels the TCA cycle and results in accumulation of certain TCA cycle metabolites, such
as  fumarate, is also important for induction of trained immunity. Aspartate consumption from the medium is also increased in trained monocytes and macrophages, while
the  cholesterol synthesis pathway appears to be an essential metabolic pathway as well, as shown by inhibition of trained immunity by statins. Several metabolites that
accumulate in trained monocytes and macrophages could play a role in the induction of epigenetic modulators, such as succinate and fumarate for antagonizing histone or
DNA  demethylation, and acetyl-CoA as an essential substrate for acetylating processes.
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.2. Tricarboxylic acid cycle
A crucial pathway of energy metabolism in the cell is repre-
ented by the TCA cycle, leading to oxidation of various substrates,
ncluding pyruvate coming from glycolysis. After induction of
rained immunity by -glucan, trained macrophages display a
ecreased basal and maximum oxygen consumption, suggestive
or a decrease in use of OxPhos [29]. However, although OxPhos is
ecreased, the TCA cycle is not completely shut down, with con-
entrations of several metabolites in the TCA cycle such as citrate,
uccinate and fumarate being increased compared to non-trained
acrophages. Increased citrate concentrations might serve as a
ource for fatty acid synthesis, as citrate was shown to inhibit gly-
olysis and TCA cycle metabolism, whereas gluconeogenesis and
ipid and sterol synthesis were induced [35–41]. Citrate can either
e produced from glycolysis via pyruvate, or it can be derived from
ther metabolites, such as glutamine, which can be converted into
-ketoglutarate and enter the TCA cycle [35,42]. The latter pathway
s especially important in conditions where the mTORC1 pathway
s active which results in Hif1 induction (e.g. trained immunity)
43], as Hif1 inhibits pyruvate dehydrogenase (PDH) and therefore
arbon incorporation of glycolysis into the TCA cycle [43,44] (Fig. 2).
hen citrate is being used as a source for lipid or sterol synthesis, it
rst should be transported from the mitochondrion into the cytosol
y the citrate carrier (CIC) where it can be converted into acetyl-CoA
y ATP citrate lyase [45] (Fig. 2). Acetyl-CoA is a acetyl donor for
istone acetylation (a histone mark that facilitates transcription)
46]. Moreover, it has been shown that acetyl-CoA derived from
oth glycolysis and glutamine induces histone acetylation of genes
f glycolytic enzymes, such as hexokinase 2, phosphofructokinase,
nd lactate dehydrogenase (LDH) [47], therefore promoting glycol-
sis. Inhibition of, or mutations in, CIC limit histone acetylation,
howing the importance of citrate in histone acetylation [48].
Succinate and fumarate concentrations are also higher in -
lucan trained monocytes and macrophages and both have been
hown to play an important role in inﬂammation [49]. Accumula-
ion of succinate and fumarate has been shown to have a stabilizing
ffect on Hif-1 (by inhibiting Prolyl hydroxylases), and thus lead
o an increase in glycolysis and IL-1 transcription [23,50,51].
part from the effect on Hif-1, succinate also signals through
he succinate receptor, which in dendritic cells results in intracel-
ular calcium mobilization and synergism with Toll-like receptor
 (TLR3) and TLR7 and promote their activity [52,53]. Succinate
lso results in succinylation of several proteins, e.g. GAPDH, malate
ehydrogenase, LDH and the glutamate carrier 1. However, how
his posttranslational modiﬁcation affects the activity of these pro-
eins remains to be elucidated [23]. Lastly, succinate and fumarate
an act as an antagonist of histone and DNA demethylases. Lysine
emethylases (KDMs) of the JmjC family need -ketoglutarate as
 cofactor for the demethylation process [54] and succinate and
umarate are known to serve as antagonizing factors [54,55]. For
umarate it has also been shown that it can inhibit activity of KDM5
emethylases [12,56].
2-hydroxyglutarate concentrations are also higher in
rained monocytes, and this also has antagonizing effects
n -ketoglutarate-dependent demethylases [57]. Hence, 2-
ydroxyglutarate could also serve as an additional factor in
odulating epigenetic marks induced by -glucan.
. Future directions to study immunometabolism in
rained immunity.1. Glutamine metabolism
The metabolite glutamine has been shown to be an essential
ource of succinate and fumarate by glutamine anaplerosis and theunology 28 (2016) 425–430
GABA shunt [23], and also for citrate via the reverse TCA cycle route
[35]. It should therefore also be determined whether glutamine
metabolism is an important component of trained immunity as
well (Fig. 2). In addition, other effects of glutamine metabolism
may  inﬂuence cell activation during trained immunity. Firstly, glu-
tamate could be used for ATP production, as well as NADPH by
conversion of cytosolic malate to pyruvate. Therefore, mitochon-
drial malate needs to be transported into the cytosol by the malate
shuttle. In addition, cytosolic pyruvate could also be used to main-
tain the NADH redox balance by conversion to lactate. Secondly,
glutamate could be used to produce acetyl CoA, which acts as a sub-
strate for histone acetyltransferases [58]; notably, H3K27Ac is an
important histone mark accompanying active promoters in trained
monocytes [7]. Thirdly, in a glioblastoma cell line, glutamine has
been shown to contribute to the production of cholesterol and fatty
acids, two pathways that were signiﬁcantly upregulated in trained
monocytes [7]. Glutamine enters the TCA cycle via -ketoglutarate
or succinate and is metabolized to citrate (or goes in the reverse
direction [59]) that can be converted into cytosolic acetyl CoA,
which can be used as a direct fuel for cholesterol and fatty acid
synthesis. Fourthly, glutamine could be used to produce malate,
which can be used for fueling the malate-aspartate shuttle. In this
way the reducing equivalents of mitochondrial NADH can be trans-
ported to the cytoplasm for NADPH production, where it might
serve as a cofactor in the cholesterol synthesis pathway, which
is highly induced in -glucan-induced trained immunity (Fig. 2).
Finally, inhibition of glutamine uptake in breast cancer cell lines has
been strongly correlated with reduction of H3K4me3 of essential
genes, modulated by reduced expression of the methyltransferases
SETD1 and ASH2L [60].
3.2. Aspartate metabolism
When consumption of amino acids from the medium of non-
trained and -glucan-trained human macrophages was compared,
consumption of aspartate was  shown to be highly induced in
trained macrophages. Metabolism of aspartic acid serves several
roles, as it is part of the urea cycle, gluconeogenesis, and the malate-
aspartate shuttle, it is important for inosine formation in purine
metabolism, and is a precursor for several amino acids, including
methionine [61]. Aspartate could therefore contribute in several
ways to the induction of trained immunity. Firstly, aspartate might
act by upregulating the malate-aspartate shuttle, which would
result in a transition of the reducing equivalents of mitochon-
drial NADH to NADPH production in the cytoplasm, where it might
serve as an essential metabolite for upregulated cholesterol syn-
thesis (Fig. 2). Secondly, aspartate might serve as fuel for purine
production, which is upregulated in -glucan-trained cells via the
penthose phosphate pathway (PPP) [62]. Thirdly, aspartate can be
used as a source, via transamination of oxaloacetic acid, which
together with acetyl-CoA forms citrate [35] (Fig. 2). Finally, aspar-
tate might serve for the production of essential amino acids such as
methionine, which also serves, just as other metabolic pathways,
such as folate and choline metabolism, as an essential cofactor for
DNA and histone methyltransferases [63,64].
3.3. Cholesterol synthesis
Analysis of transcriptome data of -glucan trained macrophages
revealed that also the cholesterol synthesis pathway was also
highly induced [7]. How the cholesterol synthesis pathway con-
tributes to the phenotype of trained immunity is still to be
elucidated. However, a plausible hypothesis for this effect is that
cholesterol remodels the cell membrane of trained cells, which
could mediate increased signal transduction upon restimulation,
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. Future directions to target disease
Immunometabolism is a ﬁeld that has gained more interest the
ast several years, and has been shown to be involved in immune
ctivation in several diseases such as infections [66,67], autoin-
ammatory disorders and cardiovascular diseases [68]. Moreover,
n post-sepsis immunoparalysis, we have shown that the cellular
etabolism of monocytes had broad defects and that reversing
hese defects could at least partially restore the immunological
unction of these cells [8,69]. Therefore, modulation of cellular
etabolism has great potential as a therapeutic in immune-
ediated diseases. In autoinﬂammatory diseases, atherosclerosis
r insulin resistance and diabetes in which monocytes and
acrophages are thought to be skewed towards a proinﬂammatory
roﬁle, inhibition of certain metabolic pathways may  represent a
alid approach to target disease activity [14,68,70–73]. Moreover,
he role played by cellular metabolic pathways for the induc-
ion of trained immunity may  also represent a novel therapeutic
pproach in immunodeﬁciencies. Induction of metabolic pathways
mportant for trained immunity should be attempted to restore
mmune function during sepsis-induced immunoparalysis. In addi-
ion, these approaches could also be used to improve the immune
esponsiveness in vulnerable groups such as elderly and infants that
ave decreased immune function and are more prone to infectious
iseases [74,75].
In conclusion, boosting or inhibiting the innate immune system
as several potential beneﬁcial effects in different kinds of medical
ettings and modulating cellular metabolism of immune cells is a
romising new approach to reach this goal.
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